IL-34 Levels in Various Types of Periodontitis
Critical Role of Interleukin-34 in Gingival Crevicular Fluid as a Potential Markers of Inflammation in Patients With Periodontitis
1 other identifier
interventional
60
0 countries
N/A
Brief Summary
The objective of this study is to 1) identification of the impact of IL-34 on the pathogenesis of periodontal disease and determine whether any relationship among the existing levels of Gingival crevicular fluid (GCF) Interleukin 34( IL-34 )and GCF Receptor activator of nuclear factor -kB ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio, as a mediator of bone resorption 2) analysis of the impact of non-surgical periodontal treatment on GCF IL-34 levels in patients with chronic periodontitis (CP) and aggressive periodontitis (AgP) and 3) to correlate between biochemical markers and clinical recordings
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2015
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2017
CompletedFirst Submitted
Initial submission to the registry
January 8, 2020
CompletedFirst Posted
Study publicly available on registry
January 10, 2020
CompletedJanuary 10, 2020
January 1, 2020
1.1 years
January 8, 2020
January 8, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
gingival crevicular fluid IL-34 level
gingival crevicular fluid IL-34 levels change from baseline to at 6th week
6th week
Secondary Outcomes (6)
Gingival crevicular fluid RANKL level
6th week
Gingival crevicular fluid OPG level
6th week
Plaque index
6th week
Gingival index
6th week
bleeding on probing
6th week
- +1 more secondary outcomes
Study Arms (3)
periodontally healthy group
NO INTERVENTIONControl
Chronic Periodontitis
ACTIVE COMPARATORnon-surgical periodontal treatment was performed
Aggressive Periodontitis
ACTIVE COMPARATORnon-surgical periodontal treatment was performed
Interventions
scaling and root planing were performed
Eligibility Criteria
You may qualify if:
- CP group included 20 patients, ≥ 35 years of age, and this category was displayed as a minimum of six teeth available clinical attachment loss (AL) and pocket probing depth (PPD) ≥ 5mm. These teeth exhibited positive bleeding on probing (BOP) across a minumum 2 separate quadrants and bone loss affecting \>30 % of available teeth on clinical and radiographic inspection. The gingival index (GI) score for indications of inflammation (red color and edema of the gingival margin) was \>1 for the CP group.
- AgP group included 20 patients, \<35 years of age, and cases showed PPD≥ 5mm with at least six teeth and radiographic evidence of alveolar bone loss. At least three of these six teeth with PPD ≥ 5 mm were not molars or incisors. These patients showed severe periodontal tissue devastation and decrease of periodontal support conflicting with age and plaque levels.
- Control group included 20 participants and they presented PPD ≤ 3mm, GI=0 (nonavailable of clinical inflammation), absence of alveolar bone loss (e.g., distance between the cemento-enamel junction and the bone crest was \<3mm in\> 95% of proximal tooth sites).
- All participants had minimum 20 teeth and their overall systematic health
You may not qualify if:
- lactation
- pregnancy
- current and ex-smoking habits
- undergone nonsurgical periodontal therapy and prescription of antibiotics or non-steroidal anti-inflammatory medication within the previous 6 months or surgical periodontal treatment within the preceding year
- postmenopause
- systemic conditions such as; diabetes mellitus, cancer, cardiovascular and respiratory diseases, rheumatoid arthritis, osteoporosis, or immunologic disorders, that might cause progress of periodontal disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Umut Ballı, PhD, DDS
Bülent Ecevit University Faculty of Dentistry
- PRINCIPAL INVESTIGATOR
Figen Öngöz Dede, PhD, DDS
Ordu University
- STUDY CHAIR
Şeyma Bozkurt Doğan, PhD, DDS
Ankara Yildirim Beyazıt University
- PRINCIPAL INVESTIGATOR
Erdim Sertoğlu, PhD, DDS
Ankara Sağlık Bilimleri University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
January 8, 2020
First Posted
January 10, 2020
Study Start
January 1, 2015
Primary Completion
February 1, 2016
Study Completion
May 1, 2017
Last Updated
January 10, 2020
Record last verified: 2020-01